


Contact:
Bill Enright
President & CEO
Phone: 205-909-3751
Email: enright@vaxin.com

**VAXIN TO PRESENT AT THE RODMAN & RENSHAW 1OTH ANNUAL HEALTHCARE CONFERENCE**

**Birmingham, Alabama** – November 5, 2008 – Vaxin Inc., an emerging vaccine company today announced that Bill Enright, President and Chief Executive Officer of Vaxin, will present a corporate update at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on Wednesday, November 12, 2008 at 4:30 p.m. Eastern Time.

Vaxin has recently announced significant progress toward its clinical and corporate goals including:

- The initiation of a Phase I human clinical study of the Company's lead influenza vaccine being developed to protect against highly-virulent strains of influenza, including those that could result in a global human pandemic. The manufacturing and testing of clinical materials for this trial is supported by a grant from the National Institutes of Health (NIH) as part of the United States Government's pandemic preparedness initiative;

- Receipt of a $100,000 grant for the development of a vaccine against Propionibacterium acnes *(P. acnes)*, a leading cause of common acne. This highly competitive grant was awarded to Vaxin in collaboration with The University of California, San Diego School of Medicine and the Veteran's Medical Research Foundation by the NIH and;

- Receipt of a $1.0 million grant to fund the ongoing development of the Company's novel avian influenza vaccine. This Small Business Innovation Research (SBIR) grant was awarded to Vaxin in collaboration with researchers at Auburn University in Auburn, Alabama and the United States Department of Agriculture's Southeastern Poultry Lab in Athens, Georgia.

About Vaxin:
Vaxin Inc. is an emerging clinical stage vaccine company developing needle-free, single dose highly effective vaccines. These molecular vaccines are safely administered either in the nose or on the skin, taking the battle against diseases to the immune system's front lines where the diseases are attacking, rather than injecting the vaccine inside the body where the body's

immune response is actually weaker. This also allows Vaxin's vaccines to be mass administered by personnel without sophisticated medical training.

As a vaccine delayed may be a vaccine denied, it is crucial to produce vaccines in a timely manner, especially in the event of a pandemic or bioterrorist attack. The company's technology platform also provides a critical tool for the rapid production of vaccines against influenza, avian influenza, anthrax, and Alzheimer's disease utilizing molecular techniques and state of the art cell culture based manufacturing. Vaxin's vaccines are not dependent on chicken eggs and can therefore be more reliably produced even in the event of avian epidemics.

Vaxin's unique technology was developed by Dr. De-chu C. Tang, Vaxin's scientific founder and Vice President of Research. Unlike current vaccines, which typically use a weakened form of the targeted disease, such as the influenza virus, Vaxin's molecular vaccines are created by inserting only a piece of the influenza virus, the antigen, into a benign delivery vehicle. This "Trojan Horse" method increases the safety of the vaccine and virtually eliminates the risk of a vaccine reverting to a disease causing agent. Needle-free, non-replicating, single-dose molecular vaccines also have many other advantages. Patients clearly prefer vaccines which are not injected because there is no fear of needles or the pain they can cause.

Vaxin's technology also has applications for animal health uses. Automated *in ovo* (in the egg) vaccination is the method of choice for the mass immunization of poultry because of the ease of administration and lower costs. Unlike most technologies that have been tried, Vaxin's technology provides the ability to administer a protective vaccine *in ovo* without harming the embryo.

Forward-looking statements:
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

# # #